6564 Stock Overview
Enimmune corporation operates as a biopharmaceutical Research and development, and marketing company in Taiwan.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Enimmune corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NT$34.10 |
| 52 Week High | NT$55.50 |
| 52 Week Low | NT$31.40 |
| Beta | 0.50 |
| 1 Month Change | 2.25% |
| 3 Month Change | -10.62% |
| 1 Year Change | -32.34% |
| 3 Year Change | -50.58% |
| 5 Year Change | 41.91% |
| Change since IPO | 2.68% |
Recent News & Updates
Recent updates
Shareholder Returns
| 6564 | TW Biotechs | TW Market | |
|---|---|---|---|
| 7D | 4.9% | -6.0% | -5.7% |
| 1Y | -32.3% | -25.8% | 23.8% |
Return vs Industry: 6564 underperformed the TW Biotechs industry which returned -25.8% over the past year.
Return vs Market: 6564 underperformed the TW Market which returned 23.8% over the past year.
Price Volatility
| 6564 volatility | |
|---|---|
| 6564 Average Weekly Movement | 3.4% |
| Biotechs Industry Average Movement | 4.7% |
| Market Average Movement | 4.6% |
| 10% most volatile stocks in TW Market | 8.5% |
| 10% least volatile stocks in TW Market | 2.1% |
Stable Share Price: 6564 has not had significant price volatility in the past 3 months.
Volatility Over Time: 6564's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 42 | n/a | www.enimmune.com.tw |
Enimmune corporation operates as a biopharmaceutical Research and development, and marketing company in Taiwan. Its products include Tuberculin PPD RT23 SSI, an approved drug for tuberculin test to determine whether the patient is infected with tuberculosis. The company is also involved in the development of vaccines to prevent various infectious diseases, such as enterovirus, pneumonia, norovirus, dengue fever virus, Middle East respiratory syndrome coronavirus, etc. Enimmune corporation was founded in 2014 and is based in Taichung City, Taiwan.
Enimmune corporation Fundamentals Summary
| 6564 fundamental statistics | |
|---|---|
| Market cap | NT$2.24b |
| Earnings (TTM) | -NT$223.74m |
| Revenue (TTM) | NT$43.49m |
51.6x
P/S Ratio-10.0x
P/E RatioIs 6564 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 6564 income statement (TTM) | |
|---|---|
| Revenue | NT$43.49m |
| Cost of Revenue | NT$66.87m |
| Gross Profit | -NT$23.37m |
| Other Expenses | NT$200.37m |
| Earnings | -NT$223.74m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.40 |
| Gross Margin | -53.74% |
| Net Profit Margin | -514.42% |
| Debt/Equity Ratio | 10.0% |
How did 6564 perform over the long term?
See historical performance and comparison